uniQure will present its third‑quarter 2025 financial results on Nov. 10, 2025, following a conference call at 8:30 a.m. ET. The company will discuss the quarter that ended September 30, 2025, and answer investor questions.
The announcement follows the company’s Q1 2025 results, which showed a net loss of $43.6 million and a cash balance of $409 million. In Q3 2024, revenue was $2.3 million with a net loss of $44.4 million, indicating a modest decline in revenue and a slight improvement in loss margin.
Analysts have set consensus estimates for the upcoming quarter, projecting a loss of $0.85 to $0.87 per share and revenue between $4.46 million and $6.93 million. These expectations reflect the company’s ongoing investment in its gene‑therapy pipeline and the anticipated impact of regulatory milestones.
uniQure’s pipeline remains a key driver of investor interest. The company’s Huntington’s disease candidate, AMT‑130, has received Breakthrough Therapy designation from the FDA, potentially accelerating its development timeline. Other programs in hemophilia B, temporal lobe epilepsy, ALS, and Fabry disease continue to progress through clinical stages.
Management emphasized the importance of maintaining a strong cash runway to support both research and potential commercialization. The $409 million cash balance is projected to fund operations through the second half of 2027, providing a buffer for continued pipeline development and strategic initiatives.
Investors will look to the Q3 2025 results for clarity on revenue growth, cost management, and the impact of regulatory developments. The company’s guidance, if provided, will signal management’s confidence in sustaining its financial position while advancing its therapeutic portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.